Pipeline Report: August 2021 | Articles

Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin Lymphoma

August 13th 2021

Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.

Neoadjuvant Stereotactic Radiation Shows Early Safety, Feasibility in RCC Inferior Vena Cava Tumor Thrombus

August 12th 2021

Neoadjuvant stereotactic radiation followed by radical nephrectomy and thrombectomy is a safe and feasible treatment option for patients with renal cell carcinoma and inferior vena cava tumor thrombus.

Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions

August 10th 2021

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.

Maveropepimut-S Demonstrates Encouraging Activity in Recurrent Ovarian Cancer

August 10th 2021

The subcutaneously administered peptide cancer vaccine maveropepimut-S was found to produce promising activity in heavily pretreated patients with recurrent ovarian cancer.

GEN-1 Plus Neoadjuvant Chemo Appears Active, Safe in Advanced Ovarian Cancer

August 8th 2021

The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.

Novel Oncolytic Virus/Allogeneic CAR T-Cell Combo Under Development for Solid Tumors

August 4th 2021

The combination of a CF33-CD19 oncolytic virus technology and CyCART-19, is under development for use as a potential therapeutic option for patients with solid tumors.